Michael Stack1, Keith Sacco2, Riccardo Castagnoli1, Alicia A Livinski3, Luigi D Notarangelo1, Michail S Lionakis4. 1. Laboratory of Clinical Immunology and Microbiology, Immunodeficiency Genetics Section, NIAID, NIH, Bethesda, MD, USA. 2. Laboratory of Clinical Immunology and Microbiology, Immunodeficiency Genetics Section, NIAID, NIH, Bethesda, MD, USA. Electronic address: keith.sacco@nih.gov. 3. Division of Library Services, Office of Research Services, National Institutes of Health, Bethesda, MD, USA. 4. Laboratory of Clinical Immunology and Microbiology, Fungal Pathogenesis Section, NIAID, NIH, Bethesda, MD, USA.
Abstract
INTRODUCTION: The Bruton tyrosine kinase (BTK) regulates B cell and macrophage signaling, development, survival, and activation. Inhibiting BTK has been hypothesized to ameliorate lung injury in patients with severe COVID-19, however clinical outcome data is inconclusive. OBJECTIVE: To evaluate the clinical outcomes of BTK inhibitors (BTKinibs) in patients with COVID-19. EVIDENCE REVIEW: We searched PubMed, Embase, and Web of Science:Core on December 30, 2020. Clinical studies with at least 5 COVID-19 patients treated with BTKinibs were included. Case reports and reviews were excluded. FINDINGS: 125 articles were identified, 6 of which met inclusion criteria. The most common clinical outcomes measured were oxygen requirements (4/6) and hospitalization rate or duration (3/6). Three studies showed decreased oxygen requirements in patients who started or continued BTKinibs. All three studies that evaluated hospitalization rate or duration found favorable outcomes in those on BTKinibs. CONCLUSIONS AND RELEVANCE: BTKinib use was associated with decreased oxygen requirements and decreased hospitalization rates and duration.
INTRODUCTION: The Bruton tyrosine kinase (BTK) regulates B cell and macrophage signaling, development, survival, and activation. Inhibiting BTK has been hypothesized to ameliorate lung injury in patients with severe COVID-19, however clinical outcome data is inconclusive. OBJECTIVE: To evaluate the clinical outcomes of BTK inhibitors (BTKinibs) in patients with COVID-19. EVIDENCE REVIEW: We searched PubMed, Embase, and Web of Science:Core on December 30, 2020. Clinical studies with at least 5 COVID-19patients treated with BTKinibs were included. Case reports and reviews were excluded. FINDINGS: 125 articles were identified, 6 of which met inclusion criteria. The most common clinical outcomes measured were oxygen requirements (4/6) and hospitalization rate or duration (3/6). Three studies showed decreased oxygen requirements in patients who started or continued BTKinibs. All three studies that evaluated hospitalization rate or duration found favorable outcomes in those on BTKinibs. CONCLUSIONS AND RELEVANCE: BTKinib use was associated with decreased oxygen requirements and decreased hospitalization rates and duration.
Authors: Zhe Liu; Cornelis van 't Veer; Rudi W Hendriks; Joris J T H Roelofs; Tom van der Poll; Alex F de Vos Journal: Infect Immun Date: 2022-05-19 Impact factor: 3.609
Authors: Samuel M Rubinstein; Divaya Bhutani; Ryan C Lynch; Jeremy L Warner; Michael A Thompson; Chih-Yuan Hsu; Yu Shyr; Shailesh Advani; Ruben A Mesa; Sanjay Mishra; Daniel P Mundt; Dimpy P Shah; R Alejandro Sica; Keith E Stockerl-Goldstein; Catherine Stratton; Matthias Weiss; Alicia Beeghly-Fadiel; Melissa Accordino; Sarit E Assouline; Joy Awosika; Ziad Bakouny; Babar Bashir; Stephanie Berg; Mehmet Asim Bilen; Cecilia A Castellano; Jacob C Cogan; Devendra Kc; Christopher R Friese; Shilpa Gupta; Daniel Hausrath; Clara Hwang; Nathalie A Johnson; Monika Joshi; Anup Kasi; Elizabeth J Klein; Vadim S Koshkin; Nicole M Kuderer; Daniel H Kwon; Chris Labaki; Tahir Latif; Eric Lau; Xuanyi Li; Gary H Lyman; Rana R McKay; Gayathri Nagaraj; Amanda Nizam; Taylor K Nonato; Adam J Olszewski; Hyma V Polimera; Andrew J Portuguese; Matthew M Puc; Pedram Razavi; Rachel Rosovski; Andrew Schmidt; Sumit A Shah; Aditi Shastri; Christopher Su; Pallawi Torka; Trisha M Wise-Draper; Leyre Zubiri Journal: Blood Cancer Discov Date: 2022-05-05
Authors: Ana Fernández-Cruz; Alba Puyuelo; Lucía Núñez Martín-Buitrago; Enrique Sánchez-Chica; Carmen Díaz-Pedroche; Rosa Ayala; Manuel Lizasoain; Rafael Duarte; Carlos Lumbreras; Juan Antonio Vargas Journal: Clin Infect Pract Date: 2022-02-15
Authors: A Costanza; A Amerio; A Aguglia; G Serafini; M Amore; R Hasler; J Ambrosetti; G Bondolfi; G Sampogna; I Berardelli; A Fiorillo; M Pompili; K D Nguyen Journal: Neurosci Biobehav Rev Date: 2022-03-12 Impact factor: 9.052